Objetivo Over 450 million individuals face depression, with over 800,000 suicide deaths per year, delivering a death rate of one person every 40 seconds. These figures are set to increase as estimates put 1 out of 4 individuals in the future to face similar mental disorders at some stage of life.NPX-101 is the first product line for treating moderate to severe depression, especially the 30% of patients who are currently drug-resistant. It is a patented non-invasive bioelectronic device that delivers Transcranial Magnetic Stimulation (TMS) in the form of a wearable Magnetic Resonance Imaging (MRI) helmet with shield protection. It delivers more precise and deeper energy stimulation, for fuller more effective therapy, removing the side-effects and other treament discomforts with current day treatment. Phase 1 of the SME instrument fits into the overall company plan of NeuroPrex and Omsbar to reach the market by contributing the financial resources needed to plan a fast sound wider deployment of the NPX-101. It would importantly help to deduce the quickest routes of distribution and market uptake for its entry-point of the U.K. Ámbito científico medical and health sciencesbasic medicineneurologydementiaalzheimersocial sciencespsychologypsychotherapymedical and health sciencesclinical medicinepsychiatryposttraumatic stress disorderengineering and technologymedical engineeringdiagnostic imagingmagnetic resonance imagingmedical and health sciencesbasic medicineneurologyparkinson Programa(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.4. - Active ageing and self-management of health H2020-EU.2.1.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT) H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument H2020-EU.3.1.6. - Health care provision and integrated care Tema(s) SMEInst-06-2016-2017 - Accelerating market introduction of ICT solutions for Health, Well-Being and Ageing Well Convocatoria de propuestas H2020-SMEInst-2016-2017 Consulte otros proyectos de esta convocatoria Convocatoria de subcontratación H2020-SMEINST-1-2016-2017 Régimen de financiación SME-1 - SME instrument phase 1 Coordinador NEUROPREX EUROPE INC LTD Aportación neta de la UEn € 50 000,00 Dirección 72 GREAT SUFFOLK STREET SE1 0BL LONDON Reino Unido Ver en el mapa Pyme Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención. Sí Región London Inner London — East Lewisham and Southwark Tipo de actividad Private for-profit entities (excluding Higher or Secondary Education Establishments) Enlaces Contactar con la organización Opens in new window Participación en los programas de I+D de la UE Opens in new window Red de colaboración de HORIZON Opens in new window Coste total € 71 429,00 Participantes (1) Ordenar alfabéticamente Ordenar por aportación neta de la UE Ampliar todo Contraer todo OMSBAR LIMITED Reino Unido Aportación neta de la UEn € 0,00 Dirección 5 THE CHAMBERS, VINEYARD, ABINGDON OX14 3PX OXFORDSHIRE Ver en el mapa Pyme Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención. Sí Región South East (England) Berkshire, Buckinghamshire and Oxfordshire Oxfordshire Tipo de actividad Private for-profit entities (excluding Higher or Secondary Education Establishments) Enlaces Contactar con la organización Opens in new window Participación en los programas de I+D de la UE Opens in new window Red de colaboración de HORIZON Opens in new window Coste total Sin datos
